BioPorto

Regulatory Filings • May 3, 2011

BioPorto has received notice from its patent advisor that the NGAL cutoff
patent is issued in Japan. Thus, Bioporto has obtained the crucial IP rights
for NGAL as a method for diagnosing acute kidney injury in Japan, Europe, New
Zealand, Singapore, Hong Kong, South Africa, South Korea, Australia and Israel.
Furthermore, patent applications are pending in a number of countries,
including USA and China.

BioPorto's NGAL cutoff patent covers the cutoff or threshold level above which
NGAL indicates acute kidney injury, and a higher cutoff indicating an impending
dialysis requirement. In addition, BioPorto has an NGAL “exclusion” patent
application, which is complementary to the cutoff patent and concerns lower
values of NGAL that exclude an immediate risk of kidney damage. The NGAL
patents allow BioPorto both to secure the placement of its own products and
enforce its rights in relation to competitors, if these should sell NGAL tests
for the diagnosis of acute kidney injury without license access to the patents.

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide,
of whom about 4 million die. Nevertheless, there has been no real progress in
methods of diagnosing kidney injury over the last half century. Existing
methods, such as serum creatinine determination, only signal kidney failure
24-72 hours after the injury has taken place. In contrast, NGAL rises to
diagnostic levels within a few hours of kidney injury and thus enables the
physician to make vital clinical decisions before the damage progresses to
potentially fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will contribute to
reducing hospital costs in the management of kidney injury and its
consequences.

     Further details from:

     Christina Thomsen, Investor Relations

     Phone 45 29 00 00, mail investor@bioporto.com